RET and non-small cell lung carcinoma: Recently the US Food and Drug Administration (FDA) has approved therapies targeting RET fusions, RETVMO (selpercatinib) and GAVRETO (pralsetinib) as well as MET exon 14-skipping variants, TABRECTA (capmatinib) in NSCLC.